RecruitingPhase 2NCT05375734
Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma
Sponsor
Second Affiliated Hospital of Nanchang University
Enrollment
32 participants
Start Date
Aug 17, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Tislelizumab in combination with anlotinib for people with immunotherapy, pulmonary pleomorphic carcinoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTislelizumab in combination with anlotinib
Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05375734
Related Trials
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
NCT070891991 location
EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER
NCT072670001 location
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
NCT073590401 location
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
NCT071360771 location
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
NCT075384791 location